Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2008
07/24/2008WO2008005986A3 Condoms with lubricant compositions and packaging providing enhanced functionality
07/24/2008WO2008005560A8 Prevention of thrombotic disorders with active vitamin d compounds
07/24/2008WO2008005538A3 Methods of using igf1r and abl kinase modulators
07/24/2008WO2008002777A3 An anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof
07/24/2008WO2007149865A3 Methods and compositions related to inhibition of ceramide synthesis
07/24/2008WO2007146841A3 Collagen cross-linking agents on dental restorative treatment and preventive dentistry
07/24/2008WO2007146226A3 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
07/24/2008WO2007143163A3 Pharmaceutical compositions for sustained release of phenyephrine
07/24/2008WO2007137030A3 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
07/24/2008WO2007136989A3 Compounds and methods for modulating expression of dgat2
07/24/2008WO2007136615A3 Combination cancer therapy
07/24/2008WO2007134236A3 Imaging agents and methods
07/24/2008WO2007134169A9 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
07/24/2008WO2007131047A3 Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
07/24/2008WO2007124757A3 Use of escitalopram for improving cognition
07/24/2008WO2007120839A3 C-nitroso-derived nitroxyl donors
07/24/2008WO2007120718A3 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
07/24/2008WO2007120638A3 Methods and compositions for modulating glycosylation
07/24/2008WO2007120528A3 Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
07/24/2008WO2007120364A3 Metabolites of wortmannin analogs and methods of using the same
07/24/2008WO2007115232A3 Cxcr4 modulators
07/24/2008WO2007108010B1 Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
07/24/2008WO2007106862A3 The use of statins to stimulate neurogenesis
07/24/2008WO2007106423A3 Tropane prodrugs with central nervous system activity
07/24/2008WO2007098462A3 Trans-fused chromenoisoquinolines, synthesis and methods for use
07/24/2008WO2007084383A3 Method and composition for the treatment of parkinson's disease
07/24/2008WO2007080401A8 Triazoloanilinopyrimidine derivatives for use as antiviral agents
07/24/2008WO2007077574A8 SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS
07/24/2008WO2007035425A3 Cyclopropyl amines as modulators of the histamine h3 receptor
07/24/2008WO2006138380A3 Amine-containing lipids and uses thereof
07/24/2008WO2005099724A3 Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
07/24/2008WO2005076979A3 Diagnosis and therapeutics for cancer
07/24/2008US20080177248 Use of Neurotoxin Therapy for Treatment of Urologic and Related Disorders
07/24/2008US20080177217 Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
07/24/2008US20080177108 the one radiochemical step synthesis of [18F] N-(5-Fluoro-2-phenoxyphenyl)-N-(2-(2-[18F]fluoroethoxy)-5-methoxybenzyl)acetamide; benzodiazepine receptor ligand; neuroprotectant; neurodegenerative diseases diagnostic; one radiochemical step synthesis of 18F; easy purified by-products
07/24/2008US20080177093 Use of an oxidopyrylium species as an intermediate in a chemical reaction; oxidopyrylium species is generated photochemically from a 3-hydroxychromone derivative followed by 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile
07/24/2008US20080177083 Trichomonas vaginalis infections and cecal amoeba infections; oral , intravenous and vaginal preparations; antiprotozoa agents; side effect reduction, nontoxic; superior to dextro-ornidazole and racemic ornidazole
07/24/2008US20080177082 N3 alkylated benzimidazole derivatives as mek inhibitors
07/24/2008US20080177080 Oxazole derivatives of tetracyclines
07/24/2008US20080177075 Use of zinc ion chelate compound such as 8-hydroxyquinoline for intra-vaginal administration to control of egg fertilization by sperm and for progeny sex determination and/or for reducing incidence of defective progeny;
07/24/2008US20080177071 Process for the preparation of 2- (2- (4- (bis (4-flourophenyl) methyl) -pipe razin-1-yl) ethoxy acetic acid derivatives or corresponding salt forms thereof and intermediates therefor
07/24/2008US20080177064 Dipeptidyl peptidase inhibitors
07/24/2008US20080177061 Target for therapy of cognitive impairment
07/24/2008US20080177029 Halogenation and sulfonation of a 4-hydroxy-quinolone, ring closing metathesis with 2nd generation Hoveyda's catalyst of 2-(2-(cyclopropyl-2-propenyl)aminocarbonyl)-4-hydroxy-5-alkenoyl) pyrrolidine, etherification with the quinolone; one pot process; Hepatitis C viricides
07/24/2008US20080177008 bioabsorbable coating on implant stents; blend of polyamideester copolymers with a Tg above the Tg of poly(ester amide benzyl ester); deliver bioactive agent paclitaxel, docetaxel, estradiol; high glass transition temperature provides release rate control, shelf life stability, prevent mechanical failure
07/24/2008US20080176964 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
07/24/2008US20080176956 Modified Green Tea Polyphenol Formulations
07/24/2008US20080176955 Combined administration of benzonatate and guaifenesin
07/24/2008US20080176954 For prophylaxis and therapy of cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne; stability
07/24/2008US20080176953 Administration of a neuroprotectant( brimonidine, clonidine and para-aminoclonidine) for the treatment of ocular neovascularization (CNV) and macular degeneration; Vision defects; photodynamic therapy; mixture of neuroprotective factor and neovascularization inhibitor
07/24/2008US20080176952 Management of Ophthalmologic Disorders, Including Macular Degeneration
07/24/2008US20080176951 Methods of treating gastrointestinary and genitourinary pain disorders
07/24/2008US20080176950 Treatments Using Venlafaxine
07/24/2008US20080176949 Form V can be formed by crystallization from various solvents rather than by sublimation; depression
07/24/2008US20080176948 Topical Anesthetic for Rapid Local Anesthesia and Method of Applying a Topical Anesthetic
07/24/2008US20080176947 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanoic acid prop-2-ynylamide; high potency; better bioavailability
07/24/2008US20080176946 Formulations for cancer treatment
07/24/2008US20080176945 e.g. 1-methyl-cyclohexanecarboxylic acid (3-methoxy-phenyl)-amide; topical products, oral care products, nasal care products, toilet articles, ingestible products and chewing gum
07/24/2008US20080176944 Elongase Genes and Uses Thereof
07/24/2008US20080176942 form a complex between sulforaphane, or analog thereof, and cyclodextrin
07/24/2008US20080176941 Process For the Preparation of Polynuclear Ferric Hydroxide-Saccaride Complexes
07/24/2008US20080176940 Photolabile Compounds
07/24/2008US20080176939 Compounds which inhibit beta-secretase activity and methods of use thereof
07/24/2008US20080176938 Modulation of pathogenicity
07/24/2008US20080176937 preparing a suspension of crystalline Form CG in toluene; heating said suspension at reflux; crystallizing the crystalline form; and recovering the crystalline Form M2
07/24/2008US20080176936 e.g. 1,4-hydroxy-2(3aminophenyl)amide-3(4bromobenzyl)-5(carboxymethyl-oxymethyl)pyran; integrin receptor antagonist; antiproliferative, anticarcinogenic, antiinflammatory, antidiabetic agent; improved bioavailability
07/24/2008US20080176935 kit contains avocado:soybean unsaponifiables (ASU) and green tea; attack cytokine signaling; Degenerative joint disease
07/24/2008US20080176934 for modifying fibrinolysis, for preventive and curative purposes with respect to thrombotic pathologies; inhibition of the expression of the PAI-1 gene
07/24/2008US20080176933 administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock; administering to a patient diagnosed with a gram negative bacterial infection; degree of polymerization of all the proanthocyanidins in the composition is at least about 6
07/24/2008US20080176932 Pharmaceutical Compositions Containing Baicalein And Baicalin With Synergistic Effect In Tumor Treatment
07/24/2008US20080176931 e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin
07/24/2008US20080176930 angiography; low in color, low in sodium chloride content, and substantially free of pyridine
07/24/2008US20080176929 driven by proton electro-chemical potential; reduction of concentration of free radicals and reactive oxygen species in living cell; antiproliferative, antiinflammatory agent, antioxidant, disinfectant; wound healing, grafting; composition of antioxidant, linker, and charged lipophilic compound/peptide
07/24/2008US20080176928 anti-parasitic ivermectin in order to reduce and eliminate the parasite Demodex folliculorum; combined with anti-inflammatory; reduce or eliminate the rebound effect typically encountered at the end of treatment with hydrocortisone
07/24/2008US20080176927 difimicin and one or more antioxidants, such as butylated hydroxytoluene; substantially increase shelf life; C. difficile-associated diarrhea
07/24/2008US20080176926 Hydrogenated Benzo (C) Thiophene Derivatives as Immunomodulators
07/24/2008US20080176925 Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof
07/24/2008US20080176924 Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics
07/24/2008US20080176923 particularly cis-hydroxyproline derivatives; inhibit or prevent proliferation, infiltration, invasion, angiogenesis and/or metastasization of cancer cells; 1-methyl-4-phenylaminocarbonyloxyproline ethyl ester; can be use as hybrid molecules or in combined agents; oral bioavailibility; chemical stability
07/24/2008US20080176922 Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris
07/24/2008US20080176920 Neuronal Pain Pathway Modulators
07/24/2008US20080176919 Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators
07/24/2008US20080176918 Adrenergic stimulant; 4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione; hypertension, glaucoma, spasticity, pain, attention deficit disorder
07/24/2008US20080176917 Schizophrenia; bioavailability, solubility, brain penetrancy; in vivo half life; synthesis; such as 3-[3-({4-methyl-5-[4-(pentafluoro-6-sulfanyl)phenyl]-4H-1,2,4-triazol-3-yl}thio)propyl]-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane
07/24/2008US20080176916 A-amino-n-hydroxy-acetamide derivatives
07/24/2008US20080176915 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics
07/24/2008US20080176914 Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
07/24/2008US20080176913 Transdermal compositions of pramipexole having enhanced permeation properties
07/24/2008US20080176912 Gpr40 agonists
07/24/2008US20080176911 2-{2-[2-hydroxy(3-methyl)butyrylamino]pentanoyl}amino-5-(1-methylethyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)thiazole; neurodegenerative diseases: senile dementia, Alzheimer's and Parkinson's diseases, Down's syndrome, amyloid angiopathy, cerebrovascular disorders, Pick's disease, post-traumatic dementias
07/24/2008US20080176910 Methods for prevention and treatment of arteriosclerosis and restenosis
07/24/2008US20080176909 synergistic use of angiotensin II receptor antagonist like (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate with the calcium channel blockers; calcium channel blockers containing 1,4-dihydropyridine group
07/24/2008US20080176908 Rapid onset of symptom relief; topical, oral
07/24/2008US20080176907 NOS Inhibitors For Treatment Of Motor Deficit Disorders
07/24/2008US20080176906 excellent androgen receptor antagonism, excellent pharmacokinetics; low toxicity; anticarcinogenic agents; 1-{[6-Chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile
07/24/2008US20080176905 Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
07/24/2008US20080176904 Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders
07/24/2008US20080176903 Novel Compounds with Analgesic Effect
07/24/2008US20080176902 N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide hemifumarate; chemokine receptor 1 modulation; chronic obstructive pulmonary disease, asthma; chemical stability; easy to handle; inhalant formulations
07/24/2008US20080176901 Compounds and compositions as channel activating protease inhibitors